Development of reporter gene assays to determine the bioactivity of biopharmaceuticals

Biotechnol Adv. 2020 Mar-Apr:39:107466. doi: 10.1016/j.biotechadv.2019.107466. Epub 2019 Nov 5.

Abstract

Complex structure and structure-function relationship of biopharmaceuticals require extensive analytical characterization and appropriate quality control of the products. Despite rapid development of sophisticated physicochemical techniques, biological activity measurement remains the critical role in inferring the high-order structure of biopharmaceuticals. Cell-based biological assays are mostly applied to determine the biological activity of biopharmaceuticals, however, refined biological assays are continually needed to increase their robustness. Reporter gene assays (RGAs) which are mechanism of action (MOA) related, less variable, accurate, precise, and labor-saving are becoming more and more recognized and adopted in the quality control. Here we discuss the importance of bioactivity determination, the strength and weakness of various assay formats with RGAs. We also introduce the mechanism of RGAs, and present a number of examples for RGAs to determine the bioactivity of various biopharmaceuticals, which indicate their extensive use in the screening, characterization, quality control, stability and biosimilarity study. We believe that with the rapid development of biotechnology, new strategies of bioassays based on RGAs will be more widely applied in various fields of biopharmaceuticals.

Keywords: Bioassay; Biotherapeutics; Cytokine; Hormone; Monoclonal antibody; Quality control; Reporter gene assay.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biological Assay*
  • Biological Products
  • Biotechnology
  • Genes, Reporter
  • Quality Control

Substances

  • Biological Products